文献速递胸部肿瘤

多系统免疫相关不良事件与非小细胞肺癌免疫治疗生存改善相关

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2020-01-01

这项多中心回顾性队列研究纳入623例接受抗PD-(L)1治疗的III/IV期NSCLC患者,9.3%发生多系统irAEs,最常见为肺炎合并甲状腺炎;多系统irAEs与更优的OS和PFS独立相关,良好ECOG PS和较长ICI疗程是其独立危险因素。

要点

  • 9.3%的NSCLC患者接受ICI后发生多系统irAEs。
  • 多系统irAEs与OS(aHR 0.57)和PFS(aHR 0.39)改善独立相关。
  • ECOG PS 0/1和较长ICI疗程是多系统irAEs的独立危险因素。

核心结论

  • 在晚期NSCLC接受ICI治疗的患者中,发生多系统irAEs与生存改善相关。

研究设计与样本

  • 多中心回顾性队列研究,纳入5个学术机构2007年1月至2019年1月间623例接受抗PD-(L)1单药或联合治疗的III/IV期NSCLC患者。

主要发现

  • 148例(24%)发生单一irAE,58例(9.3%)发生多系统irAEs。
  • 单药治疗中最常见的多系统irAE模式为肺炎合并甲状腺炎(n=7,14%)、肝炎合并甲状腺炎(n=5,10%)、皮炎合并肺炎(n=5,10%)、皮炎合并甲状腺炎(n=4,8%)。

临床怎么用

  • 接受ICI治疗的NSCLC患者出现多系统irAEs可能提示生存获益,但仍需密切监测和管理毒性。
  • ECOG PS较好和ICI疗程较长的患者发生多系统irAEs风险更高,应加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described. OBJECTIVE: To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with stage III/IV NSCLC, treated with anti-PD-(L)1 ICIs alone or in combination with another anticancer agent between January 2007 and January 2019. EXPOSURES: Anti-PD-(L)1 monotherapy or combinations. MAIN OUTCOMES AND MEASURES: Multisystem irAEs were characterized by combinations of individual irAEs or organ system involved, separated by ICI-monotherapy or combinations. Median progression-free (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Differences in PFS and OS between irAE groups were assessed by multivariable models. Risk for multisystem irAE was estimated as odds ratios by multivariable logistic regression. RESULTS: The 623 patients included in the study were mostly men (60%, n = 375) and White (77%, n = 480). The median (range) age was 66 (58-73) years, and 148 patients (24%) developed a single irAE, whereas 58 (9.3%) developed multisystem irAEs. The most common multisystem irAE patterns in patients receiving anti-PD-(L)1 monotherapy were pneumonitis thyroiditis (n = 7, 14%), hepatitis thyroiditis (n = 5, 10%), dermatitis pneumonitis (n = 5, 10%), and dermatitis thyroiditis (n = 4, 8%). Favorable Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS = 0/1 vs 2; adjusted odds ratio [aOR], 0.27; 95% CI, 0.08-0.94; P = .04) and longer ICI duration (aOR, 1.02; 95% CI, 1.01-1.03; P < .001) were independent risk factors for development of multisystem irAEs. Patients with 1 irAE and multisystem irAEs demonstrated incrementally improved OS (adjusted hazard ratios [aHRs], 0.86; 95% CI, 0.66-1.12; P = .26; and aHR, 0.57; 95% CI, 0.38-0.85; P = . 005, respectively) and PFS (aHR, 0.68; 95% CI, 0.55-0.85; P = .001; and aHR, 0.39; 95% CI, 0.28-0.55; P < .001, respectively) vs patients with no irAEs, in multivariable models adjusting for ICI duration. CONCLUSIONS AND RELEVANCE: In this multicenter cohort study, development of multisystem irAEs was associated with improved survival in patients with advanced NSCLC treated with ICIs.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Shankar B, Zhang J, Naqash AR, et al. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020. PMID: 33119034. doi:10.1001/jamaoncol.2020.5012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。